NewAmsterdam Pharma Company N.V.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $141.8M | $151.4M | $159.4M | $86.7M |
| SG&A Expense | $106.4M | $70.4M | $37.6M | $19.5M |
| Operating Income | $-225.7M | $-176.3M | $-183.0M | $-3.6M |
| Operating Margin | -1,002.9% | -386.9% | -1,298.6% | -3.5% |
| Interest Expense | — | — | — | $287.0K |
| Pretax Income | $-203.8M | $-241.6M | $-176.9M | $-22.6M |
| Income Tax Expense | — | $-1.0K | $27.0K | — |
| Net Income | $-203.8M | $-241.6M | $-176.9M | $-22.6M |
| Net Margin | -905.7% | -530.3% | -1,255.8% | -22.0% |
| EPS (Basic) | $-1.72 | $-2.56 | $-2.15 | $-0.30 |
| EPS (Diluted) | $-1.72 | $-2.56 | $-2.15 | $-0.30 |
| Shares Outstanding (Basic) | 118.4M | 94.4M | 82.2M | 75.9M |
| Shares Outstanding (Diluted) | 118.4M | 94.4M | 82.2M | 75.9M |
| Dividends Per Share | — | — | — | — |